Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb) announced today the extension of the expiration date of the offers to…
Cellgene and bluebird bio are are encouraged by the expansion and persistence ofthe CAR T-cells, as well as the deep and durable responses with amanageable safety profile we’ve seen for bb2121 to date
Celgene Corporation’s study testing Revlimid on patients with previously untreated follicular lymphoma showed that treatment with a chemotherapy-free R2 regimen offered numerically…
Celgene Corporation has hired David V. Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO), who will join the…
Celgene Corporation (NASDAQ:CELG) has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug…
Celgene Corporation and Agios Pharmaceuticals, Inc. today announced that IDHIFA was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test.
Celgene Corporation and BeiGene have entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1…
Celgene Corporation and Agios Pharmaceuticals have reported new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-2 (IDH2) mutation.